Form 4: Alzamend Neuro Director Milton C. Ault III Reports Stock Sales

Director Milton C. Ault III reports selling Alzamend Neuro (ALZN) shares on May 12, 2025, through direct and indirect holdings.

Summary

• Milton C. Ault III, a director and 10% owner of Alzamend Neuro, Inc. (ALZN), reported changes in beneficial ownership on May 14, 2025.
• On May 12, 2025, Ault sold 1,213 shares of common stock at a weighted average price of $5.0604, with prices ranging from $5.0461 to $5.237 per share.
• Additionally, 11 shares were sold at $5.2801.
• Following these transactions, Ault directly owns 1,843 shares and indirectly owns 8,260 shares through Ault Lending, LLC, 11,068 shares through Ault Life Sciences, Inc., and 61 shares through Ault Life Sciences Fund, LLC.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of stock sales. The impact depends on the investor's interpretation of the insider's actions.

Negatives

• The reporting person sold shares, which could be interpreted negatively by some investors.

Risks

• Continued selling by major shareholders could put downward pressure on the stock price.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders buy or sell company stock. These filings are closely watched by investors for insights into management's perspective on the company's prospects.

Stakeholder Impact

• Shareholders may react to the news of the stock sale, potentially affecting the stock price.

Key Dates

Keywords

Alzamend Neuro, ALZN, Milton C. Ault III, Form 4, Beneficial Ownership, Stock Sale, Director, Ault Lending, Ault Life Sciences